254 related articles for article (PubMed ID: 12064567)
1. Clinical pharmacology of bivalirudin.
Reed MD; Bell D
Pharmacotherapy; 2002 Jun; 22(6 Pt 2):105S-111S. PubMed ID: 12064567
[TBL] [Abstract][Full Text] [Related]
2. Bivalirudin: a direct thrombin inhibitor.
Gladwell TD
Clin Ther; 2002 Jan; 24(1):38-58. PubMed ID: 11833835
[TBL] [Abstract][Full Text] [Related]
3. Percutaneous coronary intervention in patients with acute coronary syndrome: focus on bivalirudin.
Ramana RK; Lewis BE
Vasc Health Risk Manag; 2008; 4(3):493-505. PubMed ID: 18827868
[TBL] [Abstract][Full Text] [Related]
4. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
Carswell CI; Plosker GL
Drugs; 2002; 62(5):841-70. PubMed ID: 11929334
[TBL] [Abstract][Full Text] [Related]
5. Bivalirudin: an anticoagulant for acute coronary syndromes and coronary interventions.
White HD; Chew DP
Expert Opin Pharmacother; 2002 Jun; 3(6):777-88. PubMed ID: 12036417
[TBL] [Abstract][Full Text] [Related]
6. Pharmacology and clinical use of bivalirudin.
Sciulli TM; Mauro VF
Ann Pharmacother; 2002 Jun; 36(6):1028-41. PubMed ID: 12022907
[TBL] [Abstract][Full Text] [Related]
7. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.
Kleiman NS; Klem J; Fernandes LS; Rubin H; Challa S; Solomon S; Maresh K; Arora U; Klem E; Buergler J; Mathew S; Browning A; DeLao T
Am Heart J; 2002 Apr; 143(4):585-93. PubMed ID: 11923794
[TBL] [Abstract][Full Text] [Related]
8. Bivalirudin, a bivalent, thrombin specific anticoagulant as an alternative to heparin in interventional procedures as an alternative to heparin in interventional procedures.
Chew DP
Hamostaseologie; 2002 Aug; 22(3):60-6. PubMed ID: 12215763
[TBL] [Abstract][Full Text] [Related]
9. Bivalirudin: a review of the pharmacology and clinical application.
Van De Car DA; Rao SV; Ohman EM
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1673-81. PubMed ID: 21108549
[TBL] [Abstract][Full Text] [Related]
10. Bivalirudin: a new approach to anticoagulation.
Nawarskas JJ; Anderson JR
Heart Dis; 2001; 3(2):131-7. PubMed ID: 11975781
[TBL] [Abstract][Full Text] [Related]
11. Debate of adjunctive pharmacology for percutaneous coronary intervention: thrombin inhibitors and clopidogrel are enough.
Yehudai L; Feit F
J Interv Cardiol; 2006 Oct; 19(5):464-9. PubMed ID: 17020572
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin administration during percutaneous coronary intervention: emphasis on high-risk patients.
Seybert AL
Pharmacotherapy; 2002 Jun; 22(6 Pt 2):112S-118S. PubMed ID: 12064568
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
Lincoff AM; Bittl JA; Harrington RA; Feit F; Kleiman NS; Jackman JD; Sarembock IJ; Cohen DJ; Spriggs D; Ebrahimi R; Keren G; Carr J; Cohen EA; Betriu A; Desmet W; Kereiakes DJ; Rutsch W; Wilcox RG; de Feyter PJ; Vahanian A; Topol EJ;
JAMA; 2003 Feb; 289(7):853-63. PubMed ID: 12588269
[TBL] [Abstract][Full Text] [Related]
14. Bivalirudin: pharmacology and clinical applications.
Shammas NW
Cardiovasc Drug Rev; 2005; 23(4):345-60. PubMed ID: 16614733
[TBL] [Abstract][Full Text] [Related]
15. Direct thrombin inhibitors for treatment of arterial thrombosis: potential differences between bivalirudin and hirudin.
Bates SM; Weitz JI
Am J Cardiol; 1998 Oct; 82(8B):12P-18P. PubMed ID: 9809887
[TBL] [Abstract][Full Text] [Related]
16. Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
Campbell KR; Mahaffey KW; Lewis BE; Weitz JI; Berkowitz SD; Ohman EM; Califf RM
J Invasive Cardiol; 2000 Dec; 12 Suppl F():14F-9. PubMed ID: 11156729
[No Abstract] [Full Text] [Related]
17. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: results of the Comparison of Abciximab Complications with Hirulog for Ischemic Events Trial (CACHET).
Lincoff AM; Kleiman NS; Kottke-Marchant K; Maierson ES; Maresh K; Wolski KE; Topol EJ
Am Heart J; 2002 May; 143(5):847-53. PubMed ID: 12040347
[TBL] [Abstract][Full Text] [Related]
18. Anticoagulant therapy for percutaneous coronary intervention.
Rao SV; Ohman EM
Circ Cardiovasc Interv; 2010 Feb; 3(1):80-8. PubMed ID: 20160186
[No Abstract] [Full Text] [Related]
19. A randomized trial to evaluate the relative protection against post-percutaneous coronary intervention microvascular dysfunction, ischemia, and inflammation among antiplatelet and antithrombotic agents: the PROTECT-TIMI-30 trial.
Gibson CM; Morrow DA; Murphy SA; Palabrica TM; Jennings LK; Stone PH; Lui HH; Bulle T; Lakkis N; Kovach R; Cohen DJ; Fish P; McCabe CH; Braunwald E;
J Am Coll Cardiol; 2006 Jun; 47(12):2364-73. PubMed ID: 16781360
[TBL] [Abstract][Full Text] [Related]
20. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.
Mahaffey KW; Lewis BE; Wildermann NM; Berkowitz SD; Oliverio RM; Turco MA; Shalev Y; Ver Lee P; Traverse JH; Rodriguez AR; Ohman EM; Harrington RA; Califf RM;
J Invasive Cardiol; 2003 Nov; 15(11):611-6. PubMed ID: 14608128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
